Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)

BACKGROUND: Approximately 30–50% of patients with major depressive disorder can be classed as treatment resistant, widely defined as a failure to respond to two or more adequate trials of antidepressants in the current episode. Treatment resistant depression is associated with a poorer prognosis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwood, L., Taylor, R., Goldsmith, K., Romeo, R., Holland, R., Pickles, A., Hutchinson, J., Dietch, D., Cipriani, A., Nair, R., Attenburrow, M.-J., Young, A. H., Geddes, J., McAllister-Williams, R. H., Cleare, A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485607/
https://www.ncbi.nlm.nih.gov/pubmed/28651526
http://dx.doi.org/10.1186/s12888-017-1393-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485607/
https://www.ncbi.nlm.nih.gov/pubmed/28651526
http://dx.doi.org/10.1186/s12888-017-1393-0

Ejemplares similares